

Ganitumab ELISA Kit

Summary

Catalog No.	KDC29904
Alternative Names	AMG 479, CAS: 905703-97-1
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	0.156 µg/ml
Range	0.31-5 µg/mL
Recovery	80-120%
Shipping	2-8 °C
Note	For Research Use Only.

Background

Ganitumab (AMG-479) is a mAb against IGF-IR which also inhibits binding of both IGF-1 and IGF-2 ligands to IGF-IR. The therapeutic value of AMG-479 was evaluated in several preclinical settings including androgen-dependent prostate cancer, and combined with androgen-deprivation therapy. Ganitumab was found to be most potent against VCaP xenografts when it was used in combination with complete androgen-deprivation therapy. After 4 weeks of treatment, tumor volume was reduced by 72% and growth suppression was maintained over 16 weeks of treatment. These findings suggested that the use of

Recombinant Proteins & Antibodies

ganitumab in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.

Precision

CV<20%

Data Image
